{
    "pmcid": "9529347",
    "qa_pairs": {
        "How were the nanobodies targeting SARS-CoV-2 isolated according to the summary?": [
            "Using a synthetic nanobody yeast display library.",
            "By immunizing camelids and extracting their antibodies.",
            "Through chemical synthesis of known antibody sequences.",
            "By cloning and expressing human monoclonal antibodies."
        ],
        "What is the primary advantage of nanobodies over conventional monoclonal antibodies mentioned in the summary?": [
            "Enhanced tissue penetration and stability due to their small size.",
            "Higher production costs leading to increased availability.",
            "Increased immunogenicity compared to conventional antibodies.",
            "Reduced ability to bind small epitopes with high affinity."
        ],
        "What potential advantage do nanobodies have over traditional monoclonal antibodies for respiratory diseases?": [
            "Adaptability for direct delivery methods like nebulization.",
            "Higher immunogenicity leading to stronger immune responses.",
            "Larger size allowing for better coverage of viral particles.",
            "Increased production time due to complex synthesis processes."
        ],
        "What structural feature of biparatopic nanobodies contributes to their enhanced neutralizing ability?": [
            "A unique 'twinned-S' conformation bridging two distinct S protein trimers.",
            "A linear conformation that allows for simultaneous binding to multiple sites.",
            "A circular structure that encapsulates the virus particles.",
            "A helical arrangement that disrupts viral membrane integrity."
        ],
        "What was found to be the most effective linker length between nanobodies for optimal neutralization?": [
            "39 amino acids.",
            "15 amino acids.",
            "25 amino acids.",
            "50 amino acids."
        ]
    }
}